Bern-based Ypsomed pivots with CHF 420 million diabetes unit sale to TecMed
Life sciences
23 April 2025
Ypsomed’s headquarters in Burgdorf, in the canton of Bern. The company has sold its diabetes care division to TecMed AG, allowing it to fully dedicate its resources to the development and global expansion of subcutaneous self-injection systems for pharmaceutical and biotech partners. | © Ypsomed
Burgdorf-based medtech Ypsomed has announced the sale of its diabetes care business to TecMed AG for up to CHF 420 million. The move marks a significant strategic shift, positioning Ypsomed as a pure-play provider of self-injection systems for pharmaceutical and biotech partners worldwide.
TecMed AG, also headquartered in Burgdorf and controlled by former Ypsomed chairman Willy Michel, will acquire Ypsomed Diabetes Care AG and its associated patch pump development activities. The transaction is expected to close in the second half of 2025, pending regulatory approval.
Ypsomed’s decision to focus exclusively on subcutaneous injection systems reflects its confidence in the growth potential of self-care solutions and biologic therapies. The sale proceeds will finance the expansion of Ypsomed’s injection system business, including two new production halls and a conference center at the company’s Solothurn site. The divestment also frees up capacity at the site, which will now be dedicated entirely to Ypsomed’s core business.
The diabetes care unit, best known for the mylife Loop solution and YpsoPump insulin pump, will continue operations under TecMed AG. It will be merged with TecMed’s patch pump development efforts to form a specialized player in insulin infusion systems. The new company will be based in Burgdorf and is expected to employ around 300 staff, including approximately 200 employees currently based in Solothurn who will relocate later this year.
According to Ypsomed, separating the two businesses will improve focus, agility, and long-term success for both companies. For TecMed, the acquisition creates an opportunity to build a global leader in diabetes care innovation, with a strong emphasis on patient-centered technology.
This transaction follows Ypsomed’s strategic review launched in November 2024, which attracted interest from over 20 potential buyers. TecMed ultimately emerged as the preferred partner following a comprehensive due diligence process.
Ypsomed continues to explore international growth opportunities and is currently evaluating potential locations for a new U.S. manufacturing site, scheduled to be operational by 2027.
